Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 34, Pages 5116-5123
Publisher
American Society of Clinical Oncology (ASCO)
Online
2010-11-02
DOI
10.1200/jco.2010.30.7074
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
- (2017) V. A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
- (2017) C. P. Belani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.
- (2017) R. A. Burger et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.
- (2017) M. Perol et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).
- (2017) C. P. Belani et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).
- (2017) F. F. Kabbinavar et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
- (2009) B. Johnson et al. EJC SUPPLEMENTS
- 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC
- (2009) W. Brugger et al. EJC SUPPLEMENTS
- Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
- (2009) Yu Yang Soon et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
- (2009) Christopher G. Azzoli et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
- (2009) Silvia Novello et al. LUNG CANCER
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
- (2009) G. Scagliotti et al. ONCOLOGIST
- Cancer Statistics, 2008
- (2008) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
- (2008) João Paulo da Silveira Nogueira Lima et al. EUROPEAN JOURNAL OF CANCER
- Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- (2008) Chang-Qi Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Estrogen Receptor-β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung
- (2008) Naohiro Nose et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2008) Panos M. Fidias et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
- (2008) F. de Marinis et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now